Sequence Liability Identification

Post-translational modifications such as glycosylation, deamidation, isomerization, and oxidation have the potential to reduce affinity, potency, stability, and homogeneity of an antibody, resulting in complications in downstream process development. LakePharma has developed algorithms to identify sequences within antibody variable regions that could present potential liabilities to product quality. The sequence liability identification service can help the investigator to assess whether they need to be eliminated early in the engineering process and to select liability free antibodies for further development.

Please contact LakePharma at for custom quotes and details.

Download Antibody Discovery brochure  Download PEGS Presentation - Integrated Solutions for Antibody Discovery and Beyond  View webinar: Discovery of Potent, Functional mAbs using Hybridoma and Phage Display Platforms Introduction to antibody libraries eBook
Cat.# Service Name Timeline Size Price Quantity Request
24700 Sequence Liability Identification 4 - 5 days TBD Request

VH and VL are analyzed for liabilities including, but not limited to, N-linked glycosylation, deamidation, isomerization, pyroglutamate formation, and oxidation.

Amino acid sequence of mature heavy and light chain variable regions

Report identifying potential sequence liabilities